Unique Top-selling CCRP Exams - New 2026 SOCRA Pratice Exam
Clinical Research Professional Dumps CCRP Exam for Full Questions - Exam Study Guide
NEW QUESTION # 24
The study coordinator for a new Phase III vaccine study is preparing documents for IRB/IEC submission.
According to the ICH GCP Guidelines, which of the following documents should be included in the submission?
- A. Case report forms
- B. The investigators' CVs
- C. Local lab normal ranges
- D. Recruitment materials
Answer: D
Explanation:
IRBs/IECs are responsible for ensuring that subject recruitment is ethical and not coercive.
* ICH E6(R2) 3.1.2:The IRB/IEC safeguards subjects by reviewing recruitment procedures and materials.
* 21 CFR 56.111(a)(3):Requires equitable subject selection, which extends to advertisements and recruitment.
* FDA Guidance on Recruiting Study Subjects (1998):States that "advertisements and recruitment materials must be reviewed and approved by the IRB prior to use." While CVs (D) and lab ranges (A) are essential documents for study feasibility and quality, they are not mandatory for IRB approval package. CRFs (B) are sponsor tools for data collection, not subject-facing, and thus not reviewed by IRBs.
Correct answer:C (Recruitment materials).
References:
ICH E6(R2), §3.1.2.
FDA Recruitment Guidance, 1998.
NEW QUESTION # 25
In accordance with the CFR, clinical trial sponsors are required to retain records and reports after a marketing application is approved for at least:
- A. 5 years
- B. 3 years
- C. 15 years
- D. 2 years
Answer: D
Explanation:
TheFDA record retention requirementfor investigational drug studies is clearly outlined in21 CFR 312.57 (c)and21 CFR 312.62(c).
* 21 CFR 312.57(c):"A sponsor shall retain the records and reports... for2 years after a marketing application is approvedfor the drug; or, if an application is not approved, until 2 years after shipment and delivery of the drug for investigational use is discontinued and FDA has been so notified."
* 21 CFR 312.62(c):Investigators also must retain study-related records for2 years following the date a marketing application is approvedor 2 years after the investigation is discontinued.
This requirement ensures FDA can audit investigational product data even after approval to confirm compliance and verify trial results. Longer retention (e.g., 15 years) may be institutional or sponsor policy but is not mandated by federal law.
Thus, the correct answer isA (2 years).
References:
21 CFR 312.57(c) (Sponsor record retention).
21 CFR 312.62(c) (Investigator record retention).
NEW QUESTION # 26
A physician wants to conduct research using an approved/marketed cardiac stent for use in the carotid artery, which is not an indication for which the device is approved. In this case, the physician must obtain which of the following?
- A. The Office for Human Research Protections (OHRP) and manufacturer approvals
- B. IRB/IEC and manufacturer approval
- C. IRB/IEC approval and an FDA IND
- D. IRB/IEC approval and an FDA IDE
Answer: D
Explanation:
When a physician investigates amedical device for a new use (off-label indication), FDA regulations classify this as aSignificant Risk Device Study, requiring anInvestigational Device Exemption (IDE)in addition to IRB approval.
* 21 CFR 812.20(a):"A sponsor shall submit an application to FDA for aninvestigational device exemption (IDE)if the device is to be used in a clinical investigation to determine safety and effectiveness."
* 21 CFR 812.2(b):Significant Risk device studies requireboth FDA and IRB approvalbefore initiation.
An IND (B) applies to drugs and biologics, not devices. Manufacturer permission (A, D) is not a regulatory requirement, although collaboration may be necessary. OHRP approval is not applicable.
Thus, the correct answer isC (IRB/IEC approval and an FDA IDE).
References:
21 CFR 812.20(a) (IDE submission requirements).
21 CFR 812.2(b) (Significant risk device studies).
NEW QUESTION # 27
A study will enroll 420 subjects over 3.5 years. What is expected average monthly accrual?
- A. 0
- B. 1
- C. 2
- D. 3
Answer: A
Explanation:
420 subjects ÷ 42 months (3.5 years) =10 subjects/month.
However, "expected average" often rounds up to next whole number, ensuring enrollment goals are met. Thus,
11/monthis correct.
This calculation is important for feasibility assessments and protocol planning.
References:Standard feasibility calculations (ICH E6(R2) §5.6).
NEW QUESTION # 28
In accordance with the CFR, for at least how many years after the completion of a study must the clinical investigator provide the sponsor with relevant changes to financial information?
- A. Three years
- B. Two years
- C. Five years
- D. One year
Answer: B
Explanation:
Investigators must disclosefinancial interests and arrangementsthat could affect study integrity.
* 21 CFR 54.6(e):"Clinical investigators shall update financial disclosure information during the study and for1 year following completion of the study."
* However,21 CFR 54.4(b):requires sponsors to collect financial disclosure information "before a study begins and for1 year following completion." Because the regulation requires disclosure updates for1 year post-study, the correct answer isB (Two years) is incorrect, but some interpretations mistakenly extend beyond 1 year.
#The most accurate regulation states1 year, but CCRP exams often test the CFR's precise wording.
Thus, the correct answer isB (Two years)appears in some SoCRA prep materials but legally isOne year- I will confirm:
* #Final verified:One year(Answer A).
References:
21 CFR 54.4(b) (Financial disclosure requirements).
21 CFR 54.6(e) (Update requirements).
NEW QUESTION # 29
For an investigational new drug study that has potential side effects of myalgia, arthralgia, and lethargy, which of the following could serve as an acceptable consent statement?
- A. You might develop symptoms of myalgia, arthralgia, and tiredness
- B. You might experience adverse events of myalgia, arthralgia, and lethargy
- C. You might have some mild side effects while taking the investigational drug
- D. You might have some muscle aches, joint pain, and tiredness
Answer: D
Explanation:
Consent forms must present information inlanguage understandable to the subject, avoiding technical jargon.
* 21 CFR 50.20:"The information... shall be understandable to the subject... and not include any exculpatory language."
* ICH E6(R2) 4.8.6:Information should be presented inlanguage non-technical and understandable to the subject.
Thus, while medical terms (myalgia, arthralgia) are precise, they may not be understandable to laypersons.
The correct format useslayman's terms: "muscle aches, joint pain, and tiredness" (B).
Correct answer:B.
References:
21 CFR 50.20.
ICH E6(R2), §4.8.6.
NEW QUESTION # 30
In accordance with the CFR, a sponsor must submit a protocol amendment to the FDA for which of the following?
- A. The addition of a new test that is intended to improve monitoring the subject for an adverse effect
- B. A significant change in an investigator's financial interest in the investigational product
- C. A change in the manufacturing site for the investigational product
- D. The addition of a sub-investigator with the scientific training and expertise to conduct the investigation
Answer: C
Explanation:
The U.S. Code of Federal Regulations (CFR) specifies when sponsors must notify FDA of changes to investigational drug studies under 21 CFR 312.30. A protocol amendment is required if there is:
A change to the protocol (e.g., objectives, design, subject population, dosing, or procedures).
The addition of a new investigator.
A change in the chemistry, manufacturing, or controls (CMC) that could significantly affect product quality or safety.
Among the listed options, a change in the manufacturing site (D) directly falls under significant manufacturing changes, requiring FDA submission. Changes in investigator financial interests (B) are covered under 21 CFR 54 and reported separately, not as protocol amendments. Addition of a sub-investigator (C) does not require a formal amendment, only site-level documentation and delegation log update. Addition of a monitoring test (A) may affect the protocol, but not necessarily mandate an amendment unless it changes objectives or subject safety endpoints.
Therefore, the correct answer is D. This ensures FDA oversight of product safety, efficacy, and compliance with CMC standards before investigational use.
References:
21 CFR 312.30 (Protocol amendments).
21 CFR 312.23(a)(7) (Chemistry, manufacturing, and controls information).
NEW QUESTION # 31
In accordance with ICH, which of the following is an acceptable protocol review frequency for an IRB?
- A. 24 months
- B. 36 months
- C. 6 months
- D. 12 months
Answer: D
Explanation:
IRBs must review protocols at least annually to ensure ongoing subject protection.
* 21 CFR 56.109(f):"An IRB shall conduct continuing review of research at intervals appropriate to the degree of risk, but not less than once per year."
* ICH E6(R2) 3.1.4:"The IRB/IEC should conduct continuing review of each ongoing trial at intervals appropriate to the degree of risk, but at least once per year." This establishes12 monthsas the minimum required interval. More frequent reviews (e.g., 6 months) may occur for higher-risk studies, but longer intervals (24-36 months) are not permitted.
Correct answer:B (12 months).
References:
21 CFR 56.109(f).
ICH E6(R2), §3.1.4.
NEW QUESTION # 32
In accordance with the ICH E2A Guideline, the sponsor must report an adverse event that is life-threatening, unexpected, and associated with the investigational drug to the regulatory authority as soon as possible but no later than how many calendar days after first knowledge of the event?
- A. 7 days
- B. 10 days
- C. 15 days
- D. 1 day
Answer: A
Explanation:
Serious adverse events are subject to expedited reporting requirements.
* ICH E2A 3.2.2:"Fatal or life-threatening unexpected ADRs should be reported as soon as possible but no later than7 calendar daysafter first knowledge."
* ICH E2A 3.2.3:Other serious unexpected events must be reported within 15 days.
Thus, the 7-day rule applies tolife-threatening and unexpected events(as in this case).
Correct answer:B (7 days).
References:
ICH E2A, §3.2.2.
NEW QUESTION # 33
In accordance with the ICH GCP Guideline, which of the following should the investigator refer to when a subject returns unused medication at the completion of a study?
- A. The investigational pharmacy's requirements
- B. The CRO/site agreements
- C. The Investigator's Brochure
- D. The sponsor's written procedures
Answer: D
Explanation:
Handling of investigational product (IP), including returns, is governed bysponsor's written procedures.
* ICH E6(R2) 4.6.3:"The investigator/institution should maintain records of the product's delivery, the inventory, the use by each subject, and the return to the sponsor or alternative disposition."
* ICH E6(R2) 5.13.3:"The sponsor should ensure that written procedures include instructions for... the return or alternative disposition of unused product(s)." The IB (A) describes pharmacology and safety, not IP logistics. CRO agreements (C) cover contractual duties, not product return processes. Local pharmacy policies (D) may apply operationally but do not override sponsor-required procedures.
Thus, the correct answer isB (The sponsor's written procedures).
References:
ICH E6(R2), §4.6.3 (Investigator product accountability).
ICH E6(R2), §5.13.3 (Sponsor product return procedures).
NEW QUESTION # 34
In accordance with the ICH GCP Guideline, who is responsible for ensuring that all study site personnel working on a clinical trial are qualified to conduct the trial?
- A. The clinical investigator
- B. The clinical research coordinator
- C. The study monitor
- D. The sponsor
Answer: A
Explanation:
The investigator has ultimate responsibility for site staff qualifications.
* ICH E6(R2) 4.2.4:"The investigator should ensure that all persons assisting with the trial are adequately informed about the protocol, the investigational product, and their trial-related duties and functions."
* ICH E6(R2) 4.1.5:Investigator must maintain current documentation of staff qualifications.
While sponsors and monitors oversee compliance, accountability rests with theclinical investigator.
Coordinators may implement duties, but do not hold legal responsibility.
Correct answer:B (The clinical investigator).
References:
ICH E6(R2), §4.2.4.
ICH E6(R2), §4.1.5.
NEW QUESTION # 35
A study coordinator is developing an informed consent form for the first time. As per the CFR and ICH GCP Guideline, which of the following elements must be included?
- A. A disclosure of appropriate alternative procedures or courses of treatment, if any, that might be advantageous to the subject
- B. A statement confirming that the subject has received a copy of the signed consent document
- C. A note that the qualified investigator could be financially compensated by the sponsor to conduct the clinical trial
- D. An explanation of the person to contact at the sponsor for further information regarding research subjects' rights
Answer: A
Explanation:
Theinformed consent processmust include all basic elements listed in federal regulations.
* 21 CFR 50.25(a)(4):Requires "a disclosure of appropriate alternative procedures or courses of treatment, if any, that might be advantageous to the subject."
* ICH E6(R2) 4.8.10(c):Mirrors this, requiring subjects to be informed of alternatives to participation, including available standard treatments.
This ensures the ethical principle ofRespect for Persons(Belmont Report), giving subjects the autonomy to choose among reasonable medical options.
Incorrect options:
* A: Contact information must be provided, but it is for the investigator (or IRB), not sponsor.
* B: Financial disclosures may be required for IRB review, not subject-facing.
* C: Subjects do receive a copy, but it is not a required consentelementin regulations.
Correct answer:D.
References:
21 CFR 50.25(a)(4).
ICH E6(R2), §4.8.10(c).
NEW QUESTION # 36
According to the CFR, which of the following is a complete and accurate list of the signatures required on the short form consent document?
- A. The subject or else the subject's legally authorized representative; the witness
- B. The subject or else the subject's legally authorized representative; the investigator or else the investigator's designee; the witness
- C. The subject or else the subject's legally authorized representative; the investigator or else the investigator's designee
- D. The subject or else the subject's legally authorized representative
Answer: A
Explanation:
Theshort form consent processis permitted when the subject is presented with a brief written statement that they were informed of the study, supplemented by an oral presentation.
* 21 CFR 50.27(b)(2):Requires the short form to be signed by the subject (or legally authorized representative)and a witness.
* The witness ensures that oral consent was properly conveyed and understood.
* The person obtaining consent must sign aseparate written summary, but not the short form itself.
Thus, the accurate answer isA: subject (or LAR) + witness.
References:
21 CFR 50.27(b)(2).
NEW QUESTION # 37
A physician with 20 years of experience is planning to be the site investigator for a multi-center, Phase I oncology clinical trial. In accordance with the ICH GCP Guideline, which of the following documents should the physician provide to the sponsor and the IRB/IEC?
- A. A curriculum vitae
- B. Proof of citizenship
- C. A letter of recommendation from a fellow physician
- D. A copy of medical license
Answer: A
Explanation:
Investigators must provideevidence of qualificationsto conduct the study.
* ICH E6(R2) 4.1.1:"The investigator should be qualified by education, training, and experience to assume responsibility for the proper conduct of the trial."
* ICH E6(R2) 8.2.10:Essential documents include thecurriculum vitae (CV)or other documents evidencing investigator qualifications, submitted to both sponsor and IRB/IEC.
Proof of citizenship (A) and letters of recommendation (B) are irrelevant. A copy of a medical license (D) may be provided but isnot specifically requiredby ICH. The CV is the universally required document.
Thus, the correct answer isC (Curriculum vitae).
References:
ICH E6(R2), §4.1.1 (Investigator qualifications).
ICH E6(R2), §8.2.10 (Essential documents: CV).
NEW QUESTION # 38
In accordance with the ICH GCP Guideline and the CFR, who is directly responsible for ensuring that an IRB
/IEC will conduct the initial and continuing review of a study?
- A. The investigator
- B. The study coordinator
- C. The sponsor
- D. The monitor
Answer: A
Explanation:
Theinvestigatoris directly responsible for ensuring that the IRB/IEC reviews and approves the research both initially and on a continuing basis. This responsibility is not delegable to the sponsor or study staff.
* ICH E6(R2) 4.4.1:"Before initiating a trial, the investigator/institution should have written and dated approval/favorable opinion from the IRB/IEC for the trial protocol, written informed consent form, consent form updates, and any other written information to be provided to subjects."
* 21 CFR 312.66:"An investigator shall assure that an IRB that complies with the requirements... will be responsible for the initial and continuing review and approval of the proposed clinical study." This means that while the sponsor submits documents to the FDA and oversees general compliance, the investigator has the obligation to obtain and maintain IRB approvalat their site. The monitor or study coordinator may assist in documentation, but legal responsibility rests with the investigator.
Thus, the correct answer isC (The investigator).
References:
ICH E6(R2), §4.4.1 (Investigator responsibility before initiation).
21 CFR 312.66 (IRB responsibility in clinical investigations).
NEW QUESTION # 39
A Phase I clinical trial is initiating. Who is responsible for ensuring that site staff are adequately informed about trial duties?
- A. Sponsor
- B. Program manager
- C. Clinical investigator
- D. IRB/IEC
Answer: C
Explanation:
* ICH E6(R2) 4.2.4:"The investigator should ensure that all persons assisting with the trial are adequately informed about the protocol, investigational product, and trial-related duties."This responsibility cannot be delegated to sponsor or IRB.
References:ICH E6(R2), §4.2.4.
NEW QUESTION # 40
The sponsor discontinued the clinical development of an investigational product. In accordance with the ICH GCP Guidance, at least how long should the sponsor maintain all sponsor-specific essential documents?
- A. 5 years
- B. 3 years
- C. 15 years
- D. 2 years
Answer: D
Explanation:
Retention of essential documents ensures accountability and inspection readiness.
* ICH E6(R2) 5.5.12 & 8.1:Sponsors should retain essential documents "until at least2 years after the last approval of a marketing application in an ICH region and until there are no pending or contemplated marketing applicationsor at least 2 years after formal discontinuation of clinical development of the investigational product." This standard balances subject protection with practical recordkeeping. Longer durations (B-D) may apply under institutional or national rules, but ICH establishes2 years minimum.
Correct answer:A (2 years).
References:
ICH E6(R2), §5.5.12, §8.1.
NEW QUESTION # 41
An IND application must contain all EXCEPT:
- A. A cover sheet
- B. Investigator's brochure
- C. Financial disclosure information
- D. Chemistry, manufacturing, and control information
Answer: C
Explanation:
* 21 CFR 312.23(a):Requires cover sheet, CMC information, and IB.
* Financial disclosureis required separately under21 CFR 54, not part of IND content.
References:21 CFR 312.23(a); 21 CFR 54.
NEW QUESTION # 42
For a study with a significant risk investigational medical device that could optimize the effects of radiation therapy on cancer tumors, the investigational plan states mild burns are an anticipated effect. One subject developed severe burns with blistering. In accordance with the CFR, this effect must be reported to the sponsor and the IRB/IEC as soon as possible and at most how long after the investigator first learns of the effect?
- A. 10 working days
- B. 5 working days
- C. 2 working days
- D. 7 working days
Answer: A
Explanation:
In device trials,unanticipated adverse device effects (UADEs)must be promptly reported.
* 21 CFR 812.150(a)(1):"An investigator shall submit to the sponsor and the reviewing IRB a report of anyunanticipated adverse device effectas soon as possible, but in no event later than10 working days after the investigator first learns of the effect." In this case,severe burns with blisteringgo beyond the anticipated effect of mild burns listed in the investigational plan. Therefore, it qualifies as aUADEand triggers expedited reporting. Options A, B, and C are too short; the regulation specifically mandates a10 working day maximumtimeframe.
Thus, the correct answer isD (10 working days).
References:
21 CFR 812.150(a)(1) (Reporting requirements for investigators).
NEW QUESTION # 43
An unconscious patient experiencing life-threatening cardiac arrhythmias has been admitted to an emergency room. No FDA-approved treatment is available, and no legal representative is present. The clinical investigator determined that the use of an investigational antiarrhythmic drug is required. In accordance with the CFR, who must certify the investigator's determination?
- A. An independent physician
- B. The sponsor's study monitor
- C. A sub-investigator
- D. The sponsor's medical monitor
Answer: A
Explanation:
This scenario falls underemergency use of investigational drugs without informed consent.
* 21 CFR 50.23(a):Allows waiver of informed consent if subject faces a life-threatening condition, available treatments are unproven, and immediate use is required.
* 21 CFR 50.23(a)(3):Requires that "the determination... be reviewed and concurred with by a physician who is not otherwise participating in the clinical investigation." Thus, anindependent physician(not part of the trial team) must certify the necessity of emergency investigational use.
Sponsors and monitors (C, D) are not authorized by regulation to make such determinations. Sub-investigators (A) lack independence and would be conflicted.
Correct answer:B (Independent physician).
References:
21 CFR 50.23(a)(3).
NEW QUESTION # 44
Why would a Phase IV study be conducted?
- A. Different schedule of administration
- B. Different dosage
- C. Different off-label population
- D. Different marketing strategy
Answer: C
Explanation:
Phase IV studies (post-marketing) examine real-world safety and effectiveness.
* ICH E8(R1):Describes Phase IV as "studies performed after drug approval to delineate additional information including the drug's risks, benefits, and optimal use."
* They often test drugs innew or broader populationsbeyond original approval.
While dosing and schedules are Phase I-III, Phase IV focuses onnew patient populationsor long-term outcomes.
References:ICH E8(R1).
NEW QUESTION # 45
A revised protocol added genomic testing to banked tissue samples. Before shipping samples, what must the site do?
- A. Notify enrolled subjects
- B. Obtain IRB/IEC approval for revised protocol and ICF
- C. Ship under dangerous goods requirements
- D. Execute material transfer agreement
Answer: B
Explanation:
* 21 CFR 56.109(a):IRB must review and approve any protocol amendments before implementation.
* ICH E6(R2) 4.5.2:Changes affecting subjects (e.g., genomic testing) require IRB/IEC approval and updated consent.
Thus, site must first obtainIRB approval for revised protocol and ICF.
References:21 CFR 56.109(a); ICH E6(R2) §4.5.2.
NEW QUESTION # 46
......
SOCRA CCRP Exam Syllabus Topics:
| Topic | Details |
|---|---|
| Topic 1 |
|
| Topic 2 |
|
Best way to practice test for SOCRA CCRP: https://passguide.validtorrent.com/CCRP-valid-exam-torrent.html